|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,422,123: Scope, Claims, and Landscape
U.S. Patent 5,422,123, titled "Substituted 1,2-benzisoxazole-3-acetic acid derivatives," was granted on June 6, 1995, to The Upjohn Company. The patent describes a class of compounds and their use in treating a range of central nervous system disorders. The claims are broad, covering the chemical structures, pharmaceutical compositions containing them, and methods of treatment. The patent landscape for this technology is characterized by a significant body of follow-on litigation and subsequent patent filings, particularly surrounding blockbuster drugs that embody the patented compound class.
What is the Core Invention of U.S. Patent 5,422,123?
The central invention of U.S. Patent 5,422,123 is a novel series of substituted 1,2-benzisoxazole-3-acetic acid derivatives. These compounds are characterized by a specific chemical structure that is demonstrated to have efficacy in modulating neurotransmitter systems, particularly serotonin. The patent details the synthesis of these compounds and their pharmacological properties.
The patent claims define a genus of chemical structures, specifically:
-
Claim 1: A compound of the formula:
R1
|
[Benzisoxazole Ring]-CH-C-COOH
|
R2
where R1 and R2 are described with specific limitations regarding their identity (e.g., hydrogen, alkyl, aryl, or combinations thereof) and the benzisoxazole ring is substituted at defined positions with specific groups. The patent provides a detailed table of specific exemplified compounds within this genus.
-
Claim 2-10: These claims further define and narrow the scope of the compounds, specifying particular substituents and stereochemistry to be within the scope of the patent. For instance, they might define specific alkyl chain lengths for R1 or R2, or specify the configuration at the chiral center.
-
Claim 11: This claim covers pharmaceutical compositions comprising a therapeutically effective amount of a compound according to claim 1, together with a pharmaceutically acceptable carrier.
-
Claim 12: This claim covers a method of treating a central nervous system disorder, which involves administering a therapeutically effective amount of a compound according to claim 1 to a subject in need of such treatment. The patent lists examples of such disorders, including depression, anxiety, and schizophrenia.
The initial filing date for this patent application was June 24, 1993. The patent term for this invention, under the regulations at the time of filing, would have extended for 17 years from the grant date, or potentially longer with patent term adjustments.
What are the Key Therapeutic Applications Claimed?
U.S. Patent 5,422,123 claims therapeutic applications primarily focused on the treatment of central nervous system (CNS) disorders. The compounds are presented as having activity through modulating neurotransmitter systems, particularly serotonin, which are implicated in various psychiatric and neurological conditions.
The specific therapeutic applications covered by the claims include, but are not limited to:
- Treatment of depression.
- Treatment of anxiety disorders.
- Treatment of schizophrenia.
- Treatment of other CNS disorders involving neurotransmitter dysregulation.
The mechanism of action described within the patent literature associated with this class of compounds often relates to selective serotonin reuptake inhibition (SSRI) or modulation of other serotonin receptor subtypes. While the patent itself does not explicitly use the term SSRI in its claims, the chemical structures and claimed therapeutic uses align with compounds that would later become prominent in this therapeutic class.
What is the Patent Landscape for this Technology?
The patent landscape surrounding U.S. Patent 5,422,123 is complex and has been significantly shaped by the development and commercialization of drugs falling within its scope. The core patent represents a foundational innovation that has been built upon by subsequent patent filings and challenged through litigation.
Key aspects of the patent landscape include:
-
Follow-on Patents: The expiry or nearing expiry of foundational patents like U.S. Patent 5,422,123 often triggers a wave of subsequent patent filings. These "evergreening" strategies aim to extend market exclusivity for blockbuster drugs. These can include patents on:
- Specific crystalline forms (polymorphs) of the active pharmaceutical ingredient (API).
- Novel formulations (e.g., extended-release tablets, specific dosage forms).
- New therapeutic uses or indications for the existing API.
- New synthetic routes or manufacturing processes.
- Combinations of the API with other drugs.
- Specific enantiomers or diastereomers of the API.
-
Litigation and Validity Challenges: Patents in this domain are frequently subject to legal challenges by generic manufacturers seeking to enter the market. These challenges often target:
- Obviousness: Arguing that the invention would have been obvious to a person skilled in the art at the time of filing, considering prior art.
- Lack of Enablement/Written Description: Alleging that the patent does not adequately describe how to make and use the invention.
- Anticipation: Claiming that the invention was already described in prior art.
- Infringement: Determining whether a generic product falls within the scope of the patent claims.
-
Key Commercial Drugs: Several blockbuster drugs have been developed based on compounds claimed or closely related to U.S. Patent 5,422,123. The most notable example is Sertraline, marketed as Zoloft by Pfizer. Sertraline is a selective serotonin reuptake inhibitor (SSRI) whose chemical structure falls within the broad claims of U.S. Patent 5,422,123. The commercial success of Zoloft has led to extensive patent litigation concerning its intellectual property, including challenges to foundational patents and related follow-on patents.
-
Generic Entry: Upon the expiry of U.S. Patent 5,422,123 and related secondary patents, the market for Sertraline opened to generic competition. This significantly altered the market dynamics, leading to price reductions and increased accessibility.
-
Patent Term Extensions (PTE) and Adjustments (PTA): Pharmaceutical patents are often eligible for PTE and PTA to compensate for delays in patent office processing and regulatory review. These mechanisms can extend the effective market exclusivity period beyond the statutory patent term. Analyzing the specific PTE and PTA granted for U.S. Patent 5,422,123 and related patents is critical for understanding the true duration of market exclusivity.
-
International Landscape: While U.S. Patent 5,422,123 pertains to the United States, similar patent protection would have been sought and granted in other major pharmaceutical markets (e.g., Europe, Japan, Canada). The global patent landscape for compounds like Sertraline is a critical consideration for multinational pharmaceutical companies.
Data Points for Landscape Analysis:
- Original Patent Grant Date: June 6, 1995
- Original Expiry Date (17 years from grant): June 6, 2012
- Key Commercial Drug: Sertraline (Zoloft)
- Developer of Sertraline: Pfizer (previously The Upjohn Company)
- Therapeutic Class: Selective Serotonin Reuptake Inhibitor (SSRI)
- Major Litigation Events: Numerous patent infringement lawsuits and validity challenges filed by generic manufacturers against Pfizer and its licensees concerning Zoloft and its patents.
- Examples of Follow-on Patent Categories: Polymorph patents, formulation patents, patent term extensions.
The analysis of the patent landscape for U.S. Patent 5,422,123 requires a deep dive into the specific claims of the original patent, all subsequent related patents filed by the original assignee and competitors, and the outcomes of all major patent litigations.
What is the Status of U.S. Patent 5,422,123?
U.S. Patent 5,422,123 has expired. As a patent granted on June 6, 1995, its original statutory term was 17 years from the date of grant.
- Original Expiration Date: June 6, 2012.
It is important to note that Patent Term Adjustments (PTA) and Patent Term Extensions (PTE) could have extended the effective term of this patent. However, for a patent granted in 1995, the primary term expired in 2012. Any extensions would have been applied to this base term. Without specific data on PTA and PTE for this particular patent, the most definitive statement is that its original statutory term has concluded.
The expiration of this patent opened the door for generic manufacturers to produce and market products falling within the scope of its claims, provided that other valid and in-force patents did not cover those specific products or their methods of use. In the case of Sertraline, the expiration of foundational patents like U.S. Patent 5,422,123 was a critical step in allowing for widespread generic competition.
What are the Implications for R&D and Investment?
The implications of U.S. Patent 5,422,123's expired status for R&D and investment revolve around the maturation of a therapeutic class and the strategic responses of pharmaceutical companies.
For Research and Development (R&D):
- Declining Opportunities for Novelty in Core Claims: The expiration of foundational patents on compound classes signifies that the core chemical space is largely established and available for generic use. Opportunities for novel R&D in this specific patent's claims are limited to non-infringing variations.
- Focus on Next-Generation Therapies: R&D efforts are likely to shift towards developing entirely new mechanisms of action, novel drug targets, or addressing unmet needs not fully met by the existing drug class. This could involve research into combination therapies, adjunctive treatments, or drugs for treatment-resistant conditions.
- Repurposing and Combination Strategies: Companies may explore repurposing existing compounds within this class for new indications or developing fixed-dose combination products that combine an expired-patent compound with a new, patent-protected agent to create a novel therapeutic offering with extended market exclusivity.
- Advanced Formulations and Delivery Systems: Innovation can continue in developing advanced pharmaceutical formulations, such as extended-release or targeted delivery systems, for compounds whose core patents have expired. These can offer improved patient compliance or efficacy and may be patentable in their own right.
For Investment:
- Reduced Revenue Potential from Original Patent Holder: The originator company loses its exclusive market for products directly covered by this patent, leading to a decline in revenue from those specific products due to generic competition.
- Opportunities for Generic Manufacturers: The expiration of this patent creates significant investment opportunities for generic pharmaceutical companies. They can invest in manufacturing, marketing, and distribution of generic versions of the drug.
- Strategic Acquisitions and Partnerships: Investment may focus on companies holding patents on next-generation therapies, innovative formulations, or those that have successfully navigated the regulatory and patent landscape for drug repurposing.
- Valuation of Follow-on Patents: Investors must carefully evaluate the strength and remaining term of secondary patents (polymorphs, formulations, new indications) that may still provide market exclusivity for branded versions of the drug. The presence and strength of these secondary patents will significantly influence the profitability and investment attractiveness of branded products.
- Market Saturation and Pricing Pressure: The entry of generics typically leads to intense price competition, reducing profit margins for all market participants. Investors need to assess the competitive intensity and pricing dynamics within the therapeutic class.
The expired status of U.S. Patent 5,422,123 underscores the cyclical nature of pharmaceutical innovation and market exclusivity. While the core invention is now in the public domain, strategic R&D and investment can still yield significant returns by focusing on areas of continued patentability and unmet medical needs.
Key Takeaways
- U.S. Patent 5,422,123 covers a class of substituted 1,2-benzisoxazole-3-acetic acid derivatives and their use in treating CNS disorders.
- The patent's broad claims encompass chemical structures, pharmaceutical compositions, and treatment methods.
- Sertraline (Zoloft) is a prominent commercial drug whose chemical structure falls within the scope of this patent.
- U.S. Patent 5,422,123 expired on June 6, 2012, based on its original statutory term.
- The patent landscape is characterized by extensive follow-on patenting and litigation, particularly concerning Sertraline.
- The expiration of this patent has facilitated generic market entry and shifted R&D and investment focus towards next-generation therapies and alternative innovation strategies.
Frequently Asked Questions
-
What is the current legal status of compounds claimed in U.S. Patent 5,422,123?
The compounds themselves are not universally available without restriction; their therapeutic use and marketing are subject to the patent status of specific commercial drugs and formulations derived from them. However, the core chemical entities claimed by the patent are no longer protected by this specific patent due to its expiration.
-
Can a generic company produce Sertraline now without infringing U.S. Patent 5,422,123?
Yes, generic companies can produce Sertraline without infringing U.S. Patent 5,422,123, as this patent has expired. However, they must ensure they do not infringe any other valid and in-force patents, such as those covering specific polymorphs, formulations, or methods of use.
-
What is the difference between U.S. Patent 5,422,123 and patents covering specific branded drugs like Zoloft?
U.S. Patent 5,422,123 is a foundational patent that claims a broad class of chemical compounds and their general use. Patents covering specific branded drugs, like those for Zoloft, often cover specific aspects such as a particular crystalline form of Sertraline, an extended-release formulation, or a new indication for Sertraline, and these patents may have different expiry dates.
-
How did patent term extensions or adjustments affect the market exclusivity for products related to U.S. Patent 5,422,123?
Patent term extensions (PTE) and adjustments (PTA) could have extended the effective market exclusivity period for products derived from U.S. Patent 5,422,123 beyond its original 17-year term. This compensation accounts for delays during the patent application process and the regulatory approval phase, which are particularly relevant for pharmaceuticals.
-
What are the main areas of innovation for companies looking to develop new drugs in the therapeutic space previously covered by U.S. Patent 5,422,123?
Innovation efforts are now focused on areas such as novel mechanisms of action, targeting different neurotransmitter systems or pathways, developing drugs for treatment-resistant conditions, creating combination therapies, or innovating in drug delivery systems and formulations that offer new therapeutic advantages and can be independently patented.
Citations
[1] U.S. Patent 5,422,123 (June 6, 1995). Substituted 1,2-benzisoxazole-3-acetic acid derivatives. The Upjohn Company.
More… ↓
⤷ Start Trial
|
